Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 1;53(1):dyad154.
doi: 10.1093/ije/dyad154.

Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)

Daniela K van Santen  1   2   3 , Ashleigh Stewart  1   2 , Joseph S Doyle  1   4 , Mark A Stoové  1   2   5 , Jason Asselin  1 , Marina B Klein  6 , Jim Young  7 , Juan Berenguer  8   9   10 , Inmaculada Jarrin  8   11 , Karine Lacombe  12   13 , Linda Wittkop  14   15   16 , Olivier Leleux  14 , Dominique Salmon  17 , Fabrice Bonnet  14   15   18 , Andri Rauch  19 , Catrina Mugglin  19 , Gail Matthews  20 , Maria Prins  3   21   22   23 , Colette Smit  23 , Anders Boyd  3   23 , Marc van der Valk  21   23   24 , Rachel Sacks-Davis  1   2   25 , Margaret E Hellard  1   2   4   25   26 ; InCHEHC Study Group
Collaborators, Affiliations

Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)

Daniela K van Santen et al. Int J Epidemiol. .
No abstract available

Keywords: HIV; Hepatitis C; cohort studies; consortium; elimination.

PubMed Disclaimer

Conflict of interest statement

J.B. reports honoraria for advice or public speaking from Abbvie, Gilead, MSD, Janssen and ViiV Healthcare; and grants from Abbvie, Gilead, MSD and ViiV Healthcare. M.K. reports grants for investigator-initiated studies from ViiV Healthcare, AbbVie, Merck and Gilead, and consulting fees from ViiV Healthcare, AbbVie and Gilead, all outside the submitted work; is supported by a Tier I Canada Research Chair. A.R. reports support to his institution for advisory boards and/or travel grants from Abbvie, MSD, Gilead Sciences and Pfizer; and an investigator-initiated trial (IIT) grant from Gilead Sciences. All remuneration to A.R. went to his home institution and not to A.R. personally, and all remuneration was provided outside the submitted work. K.L. reports honoraria for advice or public speaking from Abbvie, Gilead, MSD, Janssen and ViiH Healthcare. F.B. reports grants from Gilead and honoraria from Gilead, ViiV Healthcare and MSD. M.P. reports unrestricted research grants and speaker/adviser fees from Gilead Sciences and MSD, all of which were paid to her institution and unrelated to the current work. M.vV. reports unrestricted research grants from Gilead and MSD; and fees for participation in advisory boards from Gilead, MSD and ViiV (all paid to his institution). JSD reports funding to his institution for investigator-initiated research from Gilead Sciences and Abbvie; and honoraria to his institution for educational events from AbbVie. L.W. reports grants/financial support for the work under consideration from the French Agency ANRS Emerging Infectious Diseases (ANRS—MIE), paid to her institution. G.M. reports grants from Gilead, Abbvie and ViiV, all paid to her institution and financial support for participating in advisory board from Gilead and ViiV. The CEASE study is supported by Gilead. I.J. reports grants from MSD and ViiV Healthcare, all paid to her institution; honoraria for lectures/presentations from Gilead and ViiV Healthcare; support from Gilead for attending meetings/travel; and support from Gilead to participate in an advisory board. M.H. reports investigator-initiated research grants from Gilead and Abbvie. D.S. reports support for attending meetings/travel from Gilead and Abvvie. M.S. reports funding from Gilead and Abbvie for investigator-initiated research unrelated to this work; and consultant fees from Gilead Sciences for activities unrelated to this work. All other authors had nothing to declare.

Figures

Figure 1.
Figure 1.
Distributions of person-years of follow-up and study visits in the International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC), stratified by cohort. Box plots have been ordered in ascending order of the median follow-up time (Panel A) and median number of visits per individual (Panel B). Visits included those occurring from cohort enrolment onwards. ACCESS, Australian Collaboration for Coordinated Enhanced Sentinel Surveillance; co-EC, Eliminating hepatitis C transmission by enhancing care and treatment among HIV co-infected individuals; CEASE: Control and Elimination within AuStralia of HEpatitis C from people living with HIV; CCC, Canadian co-infection Cohort study; MOSAIC, MSM Observational Study of Acute Infection with hepatitis C; HEPAVIH, Clinical Centres Collaborations of Subjects co-infected with HIV and HCV; SHCS, Swiss HIV cohort study; ATHENA, AIDS Therapy Evaluation in the Netherlands; SAIDCC, Saint-Antoine Infectious Disease Clinical Cohort; CoRIS, the cohort of Spanish HIV research network; AQUITAINE, ANRS CO3 AQUITAINE/AquiVIH-NA
Figure 2.
Figure 2.
(A) Annual rate of loss to follow-up (LTFU) in the International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC) using two approaches to calculate follow-up time and the number of events; and (B) annual crude mortality rate using data from cohorts systematically collecting mortality data. Panel A: Loss to follow up calculation based on two approaches to calculate the event and person-years. Panel B: Australia was excluded from this graph due to lack of systematic collection of mortality data. Follow-up started at study enrollment and ended at last known date to be alive or at death date for those who died. Data are shown until the year most cohorts provided data (i.e. 2019), except for SAIDCC providing data until the end of 2017. ACCESS, Australian Collaboration for Coordinated Enhanced Sentinel Surveillance; co-EC, Eliminating hepatitis C transmission by enhancing care and treatment among HIV co-infected individuals; CEASE, Control and Elimination within AuStralia of HEpatitis C from people living with HIV; CCC, Canadian co-infection Cohort study; MOSAIC, MSM Observational Study of Acute Infection with hepatitis C; HEPAVIH, Clinical Centres Collaborations of Subjects co-infected with HIV and HCV; SHCS, Swiss HIV cohort study; ATHENA, AIDS Therapy Evaluation in the Netherlands; SAIDCC, Saint-Antoine Infectious Disease Clinical Cohort; CoRIS, the cohort of Spanish HIV research network; AQUITAINE, ANRS CO3 AQUITAINE/AquiVIH-NA
Figure 3.
Figure 3.
Flow diagram of HCV testing in the International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC) between 2005 and 2019. The coloured streams represent changes over time in HCV testing/diagnosis status among individuals in follow-up in each calendar period, including those newly enrolled. The colour orange represents the change in HCV status in the subsequent calendar period among those classified as untested. The colour red represents the change in HCV status in the subsequent calendar period among those classified as HCV antibody-negative. The colour yellow represents the change in HCV status in the subsequent calendar period among those classified as HCV-positive. Lost to follow-up (LTFU)/death is represented in purple. HCV, hepatitis C virus; AB, antibody; HCV-positive, past or current HCV antibody or RNA positive test, HCV status, based on final HCV test within the study period; untested, no HCV test within the 5-year period and no previous HCV antibody-positive result; LTFU, lost to follow-up
See this image and copyright information in PMC

References

    1. Doyle JS, Aspinall E, Liew D, Thompson AJ, Hellard ME, Current and emerging antiviral treatments for hepatitis C infection. Br J Clin Pharmacol 2013;75(4):931–43. - PMC - PubMed
    1. Sogni P, Gilbert C, Lacombe K. et al. All-oral direct-acting antiviral regimens in HIV/hepatitis C virus–co-infected patients with cirrhosis are efficient and safe: real-life results from the prospective ANRS CO13–HEPAVIH cohort. Clin Infect Dis 2016;63:763–70. - PubMed
    1. World Health Organization. Interim Guidance for Country Validation of Viral Hepatitis Elimination. 2021. https://www.who.int/publications/i/item/9789240028395 (3 November 2023, date last accessed).
    1. Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol 2022;7:396–415. - PubMed
    1. Platt L, Easterbrook P, Gower E. et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016;16:797–808. - PubMed